enVVeno major holders fully exit stake

Former large shareholders Braeden Lichti and Northstrive Fund II LP report selling all NVNO common shares, reducing their disclosed ownership to 0%.

Rhea-AI Filing Summary

enVVeno Medical Corp (NVNO) is the subject of an amended Schedule 13D in which prior reporting holders Braeden Lichti and Northstrive Fund II LP report that they have fully exited their positions in the company’s common stock. The cover pages state that each reporting person now beneficially owns 0 shares, representing 0.00% of the outstanding common stock, with no voting or dispositive power.

Lichti sold all of his previously owned shares of enVVeno Medical Corp common stock on September 11, 2026. Northstrive Fund II LP sold all of its previously owned shares from September 11, 2026 to September 14, 2026. The amendment is designated as a final “exit” filing for both reporting persons, superseding an earlier Schedule 13D filed on February 20, 2026.

Key Figures

Beneficial ownership (Lichti): 0 shares (0.00%) Beneficial ownership (Northstrive Fund II LP): 0 shares (0.00%) Sale date for Braeden Lichti: September 11, 2026 +2 more

5 metrics

Beneficial ownership (Lichti) 0 shares (0.00%) Common stock of enVVeno Medical Corp reported after sales as of September 11, 2026

Beneficial ownership (Northstrive Fund II LP) 0 shares (0.00%) Common stock of enVVeno Medical Corp reported after sales completed by September 14, 2026

Sale date for Braeden Lichti September 11, 2026 Date on which Lichti sold all previously owned NVNO common shares

Sale period for Northstrive Fund II LP September 11–14, 2026 Period during which Northstrive Fund II LP sold all previously owned NVNO common shares

Par value per share $0.00001 per share Par value of enVVeno Medical Corp common stock

Key Terms

beneficially owned, dispositive power, Schedule 13D, exit filing, +1 more

5 terms

beneficially owned financial

"Aggregate amount beneficially owned by each reporting person 0.00"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

dispositive power financial

"Sole Dispositive Power 0.00 Shared Dispositive Power 0.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

Schedule 13D regulatory

"Previously, the Reporting Persons herein filed a with the U.S. Securities"

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

exit filing regulatory

"constitutes an exit filing for Braeden Lichti and NorthStrive Fund II LP"

Reporting Persons regulatory

"Northstrive Fund II LP ("Northstrive Fund") and Braeden Lichti (together with"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does this Schedule 13D/A mean for enVVeno Medical Corp (NVNO)?

It reports that prior reporting holders Braeden Lichti and Northstrive Fund II LP have sold all of their enVVeno Medical Corp common shares and now report 0 shares and 0.00% beneficial ownership, with no voting or dispositive power remaining.

When did Braeden Lichti sell his NVNO shares?

The filing states that on September 11, 2026, Braeden Lichti sold all of his previously owned shares of enVVeno Medical Corp common stock and no longer owns any shares of the company’s common stock.

When did Northstrive Fund II LP exit its position in NVNO?

The filing states that from September 11, 2026 to September 14, 2026, Northstrive Fund II LP sold all of its previously owned shares of enVVeno Medical Corp common stock and no longer owns any shares.

What is the current reported ownership of NVNO by the reporting persons?

Both Braeden Lichti and Northstrive Fund II LP report beneficial ownership of 0 shares of enVVeno Medical Corp common stock, representing 0.00% of the class, with no sole or shared voting or dispositive power.

Why is this Schedule 13D/A described as a final or exit filing for NVNO?

Because both reporting persons state they have sold all of their enVVeno Medical Corp common stock and now own none, the amendment is described as the final amendment to the prior Schedule 13D and constitutes an exit filing for each of them.

What type of security in NVNO is covered by this Schedule 13D/A?

The filing covers enVVeno Medical Corp common stock, with a stated par value of $0.00001 per share, which is the class of securities previously held and now fully sold by the reporting persons.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 04:01 PM Accepted by SEC EDGAR 09/15/2026 - 04:01 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

enVVeno Medical Corp

(Name of Issuer)

Common Stock, par value $0.00001 per share

(Title of Class of Securities)

29415J205

(CUSIP Number)

Ross. D. Carmel, Esq.
1185 Avenue of the Americas, 31st Floor
New York, NY, 10036
(212) 930-9700

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

09/11/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 29415J205

1

Name of reporting person

Braeden Lichti

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CANADA (FEDERAL LEVEL)

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.00 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

On September 11, 2026, Braeden Lichti sold all of his previously owned shares of enVVeno Medical Corp ("Issuer")'s common stock, par value $0.00001 per share ("Common Stock") and no longer owns any shares of Common Stock of the Issuer. Accordingly, this filing is the final amendment to the Schedule 13D and constitutes an exit filing for Mr. Lichti.

SCHEDULE 13D

CUSIP Number(s): 29415J205

1

Name of reporting person

Northstrive Fund II LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.00 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

From September 11, 2026 to September 14, 2026, Northstrive Fund II LP sold all of its previously owned shares of the Common Stock, and no longer owns any shares of Common Stock. Accordingly, this filing is the final amendment to the Schedule 13D and constitutes an exit filing for Northstrive Fund II LP.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.00001 per share
(b)	Name of Issuer: enVVeno Medical Corp
(c)	Address of Issuer's Principal Executive Offices: 70 Doppler, Irvine, CALIFORNIA , 92618.
Item 2.	Identity and Background
(a)	This Schedule 13D is filed jointly by Northstrive Fund II LP ("Northstrive Fund") and Braeden Lichti (together with Northstrive Fund, the "Reporting Persons"). The shares of Common Stock are held by Northstrive Fund and Mr. Braeden Lichti. Braeden Lichti is, as of the date of this Schedule 13D/A filing, the Manager of Northstrive Fund.
(b)	The address of each of Northstrive Fund and Mr. Lichti is 120 Newport Center Drive, Newport Beach, CA 92660.
(c)	Northstrive Fund is principally engaged in the business of investments into private and public securities. Mr. Lichti is principally engaged as the Chief Executive Officer of Northstrive Companies Inc., a California based management, advisory and investment company.
(d)	None of the Reporting Persons have, during the last five years, been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors) or been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws.
(e)	None of the Reporting Persons have, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws.
(f)	Northstrive Fund is a Delaware limited partnership. Mr. Lichti is a citizen of Canada.
Item 3.	Source and Amount of Funds or Other Consideration
	The information set forth in Item 4 is incorporated by reference herein. Mr. Lichti previously used personal funds to purchase his previously owned Common Stock. Northstrive Fund previously used working capital as the source of funds for the purchase of its previously owned Common Stock.
Item 4.	Purpose of Transaction
	On September 11, 2026, Braeden Lichti sold all of his previously owned shares of the Issuer's Common Stock and no longer owns any shares of Common Stock. From September 11, 2026 to September 14, 2026, NorthStrive Fund II LP sold all of its previously owned shares of the Common Stock, and no longer owns any shares of Common Stock. Previously, the Reporting Persons herein filed a Schedule 13D with the U.S. Securities and Exchange Commission on February 20, 2026 ("Schedule 13D"), which reported the number of shares held by each reporting person as of February 20, 2026. This Schedule 13D/A filing is the final amendment to the Schedule 13D and constitutes an exit filing for Braeden Lichti and NorthStrive Fund II LP.
Item 5.	Interest in Securities of the Issuer
(a)	For Northstrive Fund II LP, none as of February 11, 2026. For Braeden Lichti, none as of February 14, 2026.
(b)	Sole power to vote or to direct the vote: Northstrive Fund II LP: 0 shares Braeden Lichti: 13,0 shares Shared power to vote or to direct the vote: Northstrive Fund II LP: 0 shares Braeden Lichti: 0 shares Sole power to dispose or to direct the disposition of: Northstrive Fund II LP: 0 shares Braeden Lichti: 0 shares Shared power to dispose or to direct the disposition: Northstrive Fund II LP: 0 shares Braeden Lichti: 0 shares
(c)	The information set forth in Item 3 above is incorporated herein by reference.
(d)	Not applicable.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	The information in Items 3 and 4 are incorporated herein by reference.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Braeden Lichti

Signature:	/s/ Braeden Lichti
Name/Title:	Braeden Lichti, individually
Date:	09/15/2026

Northstrive Fund II LP

Signature:	/s/ Braeden Lichti
Name/Title:	Braeden Lichti/Manager
Date:	09/15/2026